Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezolizumab in Patients with Previously Untreated PD-L1-High, Locally Advanced Unresectable or Metastatic NSCLC (SKYSCRAPER-01): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Study
Year: 2025
Type: preprint
Study design: Clinical Trial
Source: SSRN Electronic Journal
DOI: 10.2139/ssrn.5487878
Authors: solange peters, Roy Herbst, Hidehito Horinouchi, Luis Paz Ares, Melissa Johnson, Benjamin J. Solomon, Mahmut Gumus, Mustafa Erman, Igor Bondarenko, Dong-Wan Kim, Enriqueta Felip, Alessandro Morabito, Maciej Bryl, Urbán László, Kaname Nosaki, Martin Reck, Raymond Meng, Chipman Stroud, Palak Kundu, Xiaohui Wen, Namrata S. Patil, Meilin Huang, Sarah Troutman, Christina Matheny, Byoung Chul Cho
Institutions: Centre Hospitalier Universitaire Vaudois, University of Lausanne, Yale University, National Cancer Center Hospital, Hospital Universitario 12 De Octubre, Sarah Cannon Research Institute, Peter MacCallum Cancer Centre, Istanbul Medeniyet University, Hacettepe University, Dnipro State Medical University, Seoul National University, Vall d'Hebron Hospital Universitari, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", National Cancer Center Hospital East, LungenClinic Grosshansdorf, Genentech, Yonsei University, Yonsei Cancer Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4414347751